Lisata Therapeutics completes patient enrollment for CENDIFOX trial
Portfolio Pulse from
Lisata Therapeutics has completed patient enrollment for its CENDIFOX trial, which evaluates the safety and efficacy of the investigational drug certepetide in combination with FOLFIRINOX-based therapies for certain cancers.
December 10, 2024 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lisata Therapeutics has completed patient enrollment for its CENDIFOX trial, which evaluates the safety and efficacy of the investigational drug certepetide in combination with FOLFIRINOX-based therapies for certain cancers.
The completion of patient enrollment in the CENDIFOX trial is a significant milestone for Lisata Therapeutics, indicating progress in their clinical development program. This could positively impact investor sentiment and the stock price in the short term as it shows advancement towards potential drug approval.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100